Active surveillance for the management of localized prostate cancer (Cancer Care Ontario guideline): American society of clinical oncology clinical practice guideline endorsement

Journal of Clinical Oncology

Volumn 34, Issue 18, 2016, Pages 2182-2190

  Chen, Ronald C ^a   Bryan Rumble, R ^b   Andrew Loblaw, D ^c   Finelli, Antonio ^d   Ehdaie, Behfar ^g   Cooperberg, Matthew R ^h   Morgan, Scott C ^e   Tyldesley, Scott ^f   Haluschak, John J ⁱ   Tan, Winston ^j   Justman, Stewart ^k   Jain, Suneil ^l  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Hematology and Oncology   (United States)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF MONTANA   (United States)

^l QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ARTICLE; CANCER RISK; CANCER SIZE; CONFLICT OF INTEREST; DIGITAL RECTAL EXAMINATION; ETHNICITY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MALE; MEDICAL SOCIETY; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; BLOOD; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR VOLUME;

DIGITAL RECTAL EXAMINATION; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOCIETIES, MEDICAL; TUMOR BURDEN;

EID: 84973661000     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.7759     Document Type: Article

References (17)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65:5-29, 2015
2. Basch E, Oliver TK, Vickers A, et al: Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 30:3020-3025, 2012
3. Dahabreh IJ, Chung M, Balk EM, et al: Active surveillance in men with localized prostate cancer: A systematic review. Ann Intern Med 156:582-590, 2012
4. Morash C, Tey R, Agbassi C, et al: Active surveillance for the management of localized prostate cancer: Guideline recommendations. Can Urol Assoc J 9:171-178, 2015
5. Klotz L, Zhang L, Lam A, et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126-131, 2010
6. Nam RK, Oliver TK, Vickers AJ, et al: Prostate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion. J Oncol Pract 8:315-317, 2012
7. Nam RK, Saskin R, Lee Y, et al: Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183:963-968, 2010
8. Eggener SE, Badani K, Barocas DA, et al: Gleason 6 prostate cancer: Translating biology into population health. J Urol 194:626-634, 2015
9. Sundi D, Ross AE, Humphreys EB, et al: African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: Should active surveillance still be an option for them? J Clin Oncol 31:2991-2997, 2013
10. Blume-Jensen P, Berman DM, Rimm DL, et al: Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res 21:2591-2600, 2015
11. Cuzick J, Berney DM, Fisher G, et al: Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106:1095-1099, 2012
12. Dall'Era MA, Denes B, Lawrence HJ, et al: Clinical utility of a 17-gene genomic prostate score (GPS) for treatment selection in men with newly diagnosed prostate cancer (PCa). J Clin Oncol 33, 2015 (suppl; abstr e16124)
13. Schoots IG, Petrides N, Giganti F, et al: Magnetic resonance imaging in active surveillance of prostate cancer: A systematic review. Eur Urol 67:627-636, 2015
14. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al: Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313:390-397, 2015
15. Roehrborn CG, Boyle P, Nickel JC, et al; ARIA3001 ARIA3002 and ARIA3003 Study Investigators: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434-441, 2002
16. Fleshner NE, Lucia MS, Egerdie B, et al: Dutasteride in localised prostate cancer management: The REDEEM randomised, double-blind, placebo-controlled trial. Lancet 379:1103-1111, 2012
17. Fleshner NE; REDEEM trial investigators: Dutasteride and active surveillance of low-risk prostate cancer. Lancet 379:1590, 2012